法舒地尔对冠心病患者介入治疗的临床研究(2)
 |
| 第1页 |
参见附件(1345KB，2页)。
[1] 丛玉隆.当代血液分析技术与临床.北京:人民卫生出版社,1997:34.
[2] Gaspardone A, Crea F,Versaci F, et al. Predictive value ofC-reactive protein after successful coronary-artery stentingin patients with stable angina. Am J Cardiol, 1998, 82(4):515-518.
[3] Pieterma A, Kofflard M, Dewitl E, et al. Late human loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation,1995, 91(5):1320 - 1325.
[4] Nagumo H,Sasaki Y,Ono Y,et al.Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells.Am J Physiol Cell Physiol,2000,278(1):C57-C65.
[5] Masumoto A , Mohri M , Shimokawa H , et al. Suppression ofcoronary artery spasm by the RhO2kinase inhibitor fasudil in pa2tients with vasospastic angina.Circulation, 2002,105 (13) :1545 - 1547.
[6] Matsumoto Y, Uwatoku T , Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent im-plantation in porcine coronary arteries : Involvement of multiple mechanisms.Arterioscler Thromb Vasc Biol, 2004,24 :181.
[7] Shimokawa H,Morishige K,Miyata K, et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesion in a porcine model in vivo. Cardiovasc Res, 2001, 51 (1) : 169-177.
您现在查看是摘要介绍页，详见PDF附件(1345KB，2页)。